Pharma’s Upcoming Messaging Battles In US Pricing Debate Foreshadowed In CBO Report
Our infographic offers the top takeaways from Congressional Budget Office report that says lower drug prices would decrease industry’s spend on research and development, while rejecting claim that costs of R&D set or impact a particular medicines price.
You may also be interested in...
Not only does the CBO’s new model make the impact of draconian changes look small, it also gives a framework for compromise that could make legislation more likely to pass Congress.
CRS poses series of questions about how a new federal agency tasked with speeding translational research for treating high-impact diseases would work, including potential downsides and whether it would duplicate government programs already in place.
Trade group’s new agenda offers few original solutions to tackle US drug costs, relying on old standbys and reminders of what medical innovation might be lost if industry is financially targeted by policy makers with a strong nod to drug manufacturers role the current pandemic.